EN
SINOVAC actively discusses COVID-19 Vaccine application and the industry development with other countries
The Egyptian delegation led by H.E. Ambassador to China Dr. Mohamed Elbadri visited the production base of Sinovac Life Sciences in Daxing, Beijing on 21 October 2021, accompanied by Chairman Weidong Yin, and Sales General Manager Helen Yang of Sinovac Group, and Deputy General Manager Weining Meng of Sinovac Life Sciences.
During the visit, H.E. Ambassador and Mr. Yin had a teleconference with the Minister of Health and Population of Egypt Prof. Hala Zayed on the supply and localization of SINOVAC's COVID-19 Vaccine, the procurement of other vaccine products, and also the cooperation of technology license. The two parties initially reached a cooperative intention on the above discussion.
On October 21, 2021, Sales General Manager Helen Yang of Sinovac Group welcomed The Philippines delegation led by Jose Santiago L. Sta. Romana, the Philippine Ambassador to China, and together with Venince Allen Carillo, the Third Secretary, and Data Dada, the Attache.
H.E. Ambassador Romana signed the delivery certification of the second batch of CHINA AID 1 million COVID-19 vaccines to the Philippines and went to the cold storage to personally turn on the temperature recorder.
Embassy of the Republic of Indonesia in Beijing invited Sales General Manager Helen Yang of Sinovac Group to join the Indonesia-China Business Forum 2021 on the theme "New Road to Business Acceleration in Digitalization, Health and Green Economy in Indonesia" on Tuesday, 19 October 2021.
The event is organized with the Directorate General of Asia Pacific and Africa, Ministry for Foreign Affairs of the Republic of Indonesia, Bank Indonesia Representative Office in Beijing, and Indonesia Chamber of Commerce in China.
Ambassador of the Republic of Indonesia to the People's Republic of China, H.E. Mr. Djauhari Oratmangun, Vice-Minister for Foreign Affairs of the Republic of Indonesia, H.E. Mr. Mahendra Siregar attendance the forum and introduced the bilateral solid relationship development between Indonesia-China and achievements made so far and future focus on health, digitalization and green economy, etc. Industries cooperation between China and Indonesia.
Helen Yang introduced Indonesia as the first country to issue EUA Certificate to China, and further Indonesia and Sinovac close cooperation on clinical, vaccine supplies to make Indonesia be the largest COVID-19 vaccines manufacturer in ASEAN (Association of Southeast Asian Nations) countries, and also illustrates the confidence in plan to help Indonesia to be the vaccines manufacture hub.
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.
SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, and mumps.
The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and was commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.
SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.
SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.
For more information, please see the Company’s website at www.sinovac.com.
Contact:
Sinovac Biotech Ltd.
PR Team
pr@sinovac.com